These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 32216207

  • 1. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY, Dong Q, Liu LR, Wei Q.
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Tommasi S, Pilato B, Carella C, Lasorella A, Danza K, Vallini I, De Summa S, Naglieri E.
    Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
    [Abstract] [Full Text] [Related]

  • 4. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
    Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.
    Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
    [Abstract] [Full Text] [Related]

  • 7. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.
    J Clin Oncol; 2017 Jul 01; 35(19):2149-2156. PubMed ID: 28384066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE.
    Clin Genitourin Cancer; 2020 Feb 01; 18(1):1-10. PubMed ID: 31653572
    [Abstract] [Full Text] [Related]

  • 10. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K.
    Prostate; 2018 Jun 01; 78(8):576-582. PubMed ID: 29508425
    [Abstract] [Full Text] [Related]

  • 11. [Methods for androgen receptor splice variant-7 detection: Advances in studies].
    Li K, Fan GR, Chen CH, Wang ZP.
    Zhonghua Nan Ke Xue; 2019 Nov 01; 25(11):1031-1035. PubMed ID: 32233239
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT.
    Clin Cancer Res; 2017 Jan 15; 23(2):363-369. PubMed ID: 27440270
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan 15; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

  • 19. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
    Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES.
    Prostate; 2016 Dec 15; 76(16):1484-1490. PubMed ID: 27404039
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.